+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H1 2019

  • ID: 4769178
  • Drug Pipelines
  • April 2019
  • Region: Global
  • 77 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Avacta Life Sciences Ltd
  • Celgene Corp
  • F. Hoffmann-La Roche Ltd
  • Numab Innovation AG
  • Provention Bio Inc
  • MORE
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H1 2019

Summary

According to the recently published report 'T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H1 2019'; T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation.

The report 'T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H1 2019' outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Report covers products from therapy areas Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Sclerosis, Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Down Syndrome, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lymphoblastic Lymphoma, Multiple Myeloma (Kahler Disease), Nodal Marginal Zone B-Cell Lymphoma, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Solid Tumor, Splenic Marginal Zone B-Cell Lymphoma, Traumatic Brain Injury, Type 2 Diabetes and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
  • The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Avacta Life Sciences Ltd
  • Celgene Corp
  • F. Hoffmann-La Roche Ltd
  • Numab Innovation AG
  • Provention Bio Inc
  • MORE
Introduction

Report Coverage

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development

Amgen Inc

Avacta Life Sciences Ltd

Celgene Corp

F. Hoffmann-La Roche Ltd

Numab Innovation AG

Provention Bio Inc

SYNIMMUNE GmbH

Tiziana Life Sciences Plc

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles

AMG-330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVA-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

blinatumomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EM-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

foralumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to target CD3E and Cells Expressing NKG2D for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

otelixizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasotuxizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-7082859 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TACSYN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teplizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones

Featured News & Press Releases

Apr 09, 2019: Provention Bio Initiates Phase 3 PROTECT clinical trial with PRV-031 (Teplizumab) in patients with recent onset Type 1 Diabetes

Mar 20, 2019: Tiziana submits IND application for oral formulation of Foralumab for treatment of NASH

Mar 06, 2019: Blinatumomab for acute lymphoblastic leukaemia for people with minimal residual disease activity in remission

Jan 23, 2019: Amgen’s Blincyto gets expanded indication for B-cell ALL in Europe

Dec 03, 2018: Amgen announces first-in-human data evaluating investigational novel BiTE Immunotherapy AMG 330 At ASH 2018

Nov 28, 2018: Tiziana announces initiation of phase 1 clinical trial with nasal administration of Foralumab, a fully human anti-cluster definition 3 monoclonal antibody (anti-CD3 mAb), in healthy volunteers

Nov 27, 2018: BLINCYTO for drip infusion 35 µg launched in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia

Nov 16, 2018: Amgen receives CHMP positive opinion to expand use Of BLINCYTO (Blinatumomab) in patients with minimal residual disease-positive B-Cell precursor Acute Lymphoblastic Leukemia

Nov 01, 2018: Roche presents early data for novel T-cell engaging bispecific antibody CD20-TCB at the American Society of Hematology 2018 Annual Meeting

Nov 01, 2018: Amgen to present new data on Blinatumomab at ASH 2018

Nov 01, 2018: Amgen to present new data on its acute myeloid leukemia drug candidate AMG 330 at ASH 2018

Sep 24, 2018: U.S. Food and Drug Administration approves application for Investigational New Drug; Phase I clinical study set to commence enrolment in late 2018

Sep 24, 2018: BLINCYTO (blinatumomab) approved in japan for the treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Aug 29, 2018: European Commission approves BLINCYTO (blinatumomab) for use in pediatric patients with philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Aug 16, 2018: Tiziana Life Sciences: filing of investigational new drug application

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Amgen Inc, H1 2019

Pipeline by Avacta Life Sciences Ltd, H1 2019

Pipeline by Celgene Corp, H1 2019

Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Pipeline by Numab Innovation AG, H1 2019

Pipeline by Provention Bio Inc, H1 2019

Pipeline by SYNIMMUNE GmbH, H1 2019

Pipeline by Tiziana Life Sciences Plc, H1 2019

Dormant Projects, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen Inc
  • Avacta Life Sciences Ltd
  • Celgene Corp
  • F. Hoffmann-La Roche Ltd
  • Numab Innovation AG
  • Provention Bio Inc
  • SYNIMMUNE GmbH
  • Tiziana Life Sciences Plc
Note: Product cover images may vary from those shown
Adroll
adroll